While Centessa Pharmaceuticals plc ADR has overperformed by 1.46%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CNTA rose by 45.25%, with highs and lows ranging from $25.31 to $9.60, whereas the simple moving average jumped by 48.12% in the last 200 days.
On October 28, 2025, Stephens started tracking Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) recommending Overweight. A report published by Wells Fargo on September 03, 2025, Initiated its previous ‘Overweight’ rating for CNTA. Oppenheimer also rated CNTA shares as ‘Outperform’, setting a target price of $40 on the company’s shares in an initiating report dated August 29, 2025. Truist Initiated an Buy rating on July 21, 2025, and assigned a price target of $30. Needham initiated its ‘Buy’ rating for CNTA, as published in its report on May 28, 2025. Chardan Capital Markets’s report from May 08, 2025 suggests a price prediction of $30 for CNTA shares, giving the stock a ‘Buy’ rating. Piper Sandler also rated the stock as ‘Overweight’.
Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Centessa Pharmaceuticals plc ADR’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -72.95% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 10.12, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and CNTA has an average volume of 1.20M. On a monthly basis, the volatility of the stock is set at 3.94%, whereas on a weekly basis, it is put at 4.53%, with a gain of 0.79% over the past seven days. Furthermore, long-term investors anticipate a median target price of $33.23, showing growth from the present price of $24.33, which can serve as yet another indication of whether CNTA is worth investing in or should be passed over.
How Do You Analyze Centessa Pharmaceuticals plc ADR Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 36.42%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 56.13% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
